Skip to main content

Table 3 Baseline predictors of ASAS20 response at three months of anti-TNF-α treatment

From: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

  

Univariate analysis

Multivariate analysis

  

OR (95% CI)

P-value

OR (95% CI)

P-value

Age (yr)†a

 

0.982 (0.959 to 1.006)

0.150

0.972 (0.947 to 0.998)

0.035

Gender

Female

1

-

 

-

 

Male

2.166 (1.185 to 3.958)

0.012

3.151 (1.580 to 6.285)

0.001

Duration of symptoms (yr)†

 

1.001 (0.976 to 1.028)

0.914

 

***

HLA-B27

Negative

1

-

 

-

 

Positive

0.779 (0.363 to 1.675)

0.523

 

***

Peripheral arthritis

Absent

1

-

 

-

 

Present

2.120 (0.876 to 5.129)

0.096

 

**

BASDAI (range 0 to 10)‡

 

0.946 (0.793 to 1.129)

0.538

 

***

ASDAS‡

 

1.458 (0.992 to 2.144)

0.055

 

*

Physician's GDA (range 0 to 10)‡

 

1.122 (0.983 to 1.282)

0.089

 

**

Patient's GDA (range 0 to 10)‡a

 

1.029 (0.882 to 1.201)

0.714

 

**

ESR (mm/h)‡a

 

1.016 (1.000 to 1.032)

0.049

1.023 (1.005 to 1.041)

0.014

CRP (mg/l)‡

 

1.021 (1.003 to 1.040)

0.025

 

*

BASFI (range 0 to 10)‡

 

0.939 (0.816 to 1.081)

0.382

 

***

Chest expansion (cm)‡a

 

1.081 (0.948 to 1.233)

0.243

 

**

Modified Schober test (cm)‡

 

1.026 (0.861 to 1.224)

0.773

 

***

Occiput to wall distance (cm)‡a

 

0.981 (0.942 to 1.022)

0.364

 

**

Lateral lumbar flexion L (cm)‡

 

1.027 (0.965 to 1.092)

0.402

 

***

Lateral lumbar flexion R (cm)‡

 

1.029 (0.968 to 1.094)

0.352

 

***

TNF-α blocking agent

ETA

1

-

 

-

 

IFX

2.045 (0.780 to 5.364)

0.146

 

**

 

ADA

0.938 (0.476 to 1.846)

0.852

 

**

  1. See Table 1 for definitions.
  2. OR refers to the risk of achieving ASAS20 response: † per year; ‡ per 1 grade or 1 point.
  3. a Significant difference (P < 0.05) between men and women at baseline.
  4. * CRP and ASDAS were not selected during forward conditional logistic regression due to the strong correlation with ESR (ESR and CRP: ρ = 0.669, P = 0.000; ESR and ASDAS: ρ = 0.412, P = 0.000). Although, higher CRP level (OR: 1.024, 95% CI: 1.004 to 1.044) and higher ASDAS level (OR: 1.728, 95% CI: 1.126 to 2.652) were also significant predictors of ASAS20 response at three months in the presence of age and gender.
  5. ** The variable was not selected during multivariate regression analysis (P ≥0.05).
  6. *** The variable was not tested in multivariate regression analysis because of a P-value > 0.3 in univariate regression analysis and no significant difference between men and women at baseline.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us